Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $77,550.00 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total value of $77,550.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,168,002.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amicus Therapeutics Stock Down 5.3 %

Shares of FOLD stock traded down $0.53 during mid-day trading on Monday, hitting $9.55. The stock had a trading volume of 3,568,187 shares, compared to its average volume of 2,823,909. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The firm has a market capitalization of $2.83 billion, a P/E ratio of -19.49 and a beta of 0.71. The firm’s 50-day moving average is $10.12 and its two-hundred day moving average is $11.11. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. The firm had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The firm’s quarterly revenue was up 27.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.18) EPS. On average, analysts predict that Amicus Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Van ECK Associates Corp increased its position in Amicus Therapeutics by 23.1% during the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 873 shares in the last quarter. Calton & Associates Inc. acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $142,000. Sage Capital Advisors llc acquired a new position in shares of Amicus Therapeutics in the second quarter valued at about $103,000. Old Well Partners LLC acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $180,000. Finally, EntryPoint Capital LLC increased its holdings in shares of Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 9,729 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on FOLD. UBS Group reduced their price objective on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, May 10th. Bank of America cut their target price on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Morgan Stanley cut their target price on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Finally, Guggenheim raised Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.